Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
- PMID: 24101045
- DOI: 10.1200/JCO.2013.50.9984
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
Abstract
Purpose: To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer.
Methods: ASCO/CAP convened an Update Committee that included coauthors of the 2007 guideline to conduct a systematic literature review and update recommendations for optimal HER2 testing.
Results: The Update Committee identified criteria and areas requiring clarification to improve the accuracy of HER2 testing by immunohistochemistry (IHC) or in situ hybridization (ISH). The guideline was reviewed and approved by both organizations.
Recommendations: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive (early stage or recurrence) breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive). Testing criteria define HER2-positive status when (on observing within an area of tumor that amounts to > 10% of contiguous and homogeneous tumor cells) there is evidence of protein overexpression (IHC) or gene amplification (HER2 copy number or HER2/CEP17 ratio by ISH based on counting at least 20 cells within the area). If results are equivocal (revised criteria), reflex testing should be performed using an alternative assay (IHC or ISH). Repeat testing should be considered if results seem discordant with other histopathologic findings. Laboratories should demonstrate high concordance with a validated HER2 test on a sufficiently large and representative set of specimens. Testing must be performed in a laboratory accredited by CAP or another accrediting entity. The Update Committee urges providers and health systems to cooperate to ensure the highest quality testing. This guideline was developed through a collaboration between the American Society of Clinical Oncology and the College of American Pathologists and has been published jointly by invitation and consent in both Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine.
Copyright © 2013 American Society of Clinical Oncology and College of American Pathologists.
Comment in
-
National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer.J Clin Oncol. 2015 Apr 10;33(11):1301-2. doi: 10.1200/JCO.2014.59.7211. Epub 2015 Mar 9. J Clin Oncol. 2015. PMID: 25753440 No abstract available.
-
Reply to E.A. Rakha et al.J Clin Oncol. 2015 Apr 10;33(11):1302-4. doi: 10.1200/JCO.2014.59.7559. Epub 2015 Mar 9. J Clin Oncol. 2015. PMID: 25753441 No abstract available.
Similar articles
-
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Arch Pathol Lab Med. 2014 Feb;138(2):241-56. doi: 10.5858/arpa.2013-0953-SA. Epub 2013 Oct 7. Arch Pathol Lab Med. 2014. PMID: 24099077 Free PMC article.
-
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382. doi: 10.5858/arpa.2018-0902-SA. Epub 2018 May 30. Arch Pathol Lab Med. 2018. PMID: 29846104
-
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.Arch Pathol Lab Med. 2007;131(1):18-43. doi: 10.5858/2007-131-18-ASOCCO. Arch Pathol Lab Med. 2007. PMID: 19548375
-
UK recommendations for HER2 assessment in breast cancer: an update.J Clin Pathol. 2023 Apr;76(4):217-227. doi: 10.1136/jcp-2022-208632. Epub 2022 Dec 23. J Clin Pathol. 2023. PMID: 36564170 Review.
-
Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.PLoS One. 2020 Nov 12;15(11):e0241775. doi: 10.1371/journal.pone.0241775. eCollection 2020. PLoS One. 2020. PMID: 33180796 Free PMC article. Review.
Cited by
-
Racial and survival disparities in inflammatory breast cancer (IBC) and non-IBC: a population-based study focused on Native Hawaiians and other Pacific Islanders.Front Oncol. 2024 May 17;14:1390080. doi: 10.3389/fonc.2024.1390080. eCollection 2024. Front Oncol. 2024. PMID: 38826792 Free PMC article.
-
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.Nat Med. 2024 Jun 2. doi: 10.1038/s41591-024-03021-7. Online ahead of print. Nat Med. 2024. PMID: 38825627
-
Bispecific antibody drug conjugates: Making 1+1>2.Acta Pharm Sin B. 2024 May;14(5):1965-1986. doi: 10.1016/j.apsb.2024.01.009. Epub 2024 Jan 20. Acta Pharm Sin B. 2024. PMID: 38799638 Free PMC article. Review.
-
BECN1 mRNA expression in breast cancer tissue; significant correlation to tumor grade.Mol Genet Genomics. 2024 May 24;299(1):56. doi: 10.1007/s00438-024-02145-2. Mol Genet Genomics. 2024. PMID: 38787424 Free PMC article.
-
Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.Br J Cancer. 2024 Jul;131(1):171-183. doi: 10.1038/s41416-024-02697-5. Epub 2024 May 17. Br J Cancer. 2024. PMID: 38760444
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous